Suppr超能文献

李-ESWT 联合VED 治疗对 PDE5i 反应不佳的糖尿病 ED 患者的疗效:一项单中心、随机临床试验。

The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial.

机构信息

Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.

Department of Andrology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Front Endocrinol (Lausanne). 2022 Jun 23;13:937958. doi: 10.3389/fendo.2022.937958. eCollection 2022.

Abstract

INTRODUCTION

Phosphodiesterase type 5-inhibitors (PDE5is) are the first-line treatment for patients with diabetes mellitus-induced erectile dysfunction (DMED), however, some patients are non-responser to PDE5is. We performed a perspective, randomized, comparative study to explore the efficacy of low intensity extracorporeal shock wave treatment (Li-ESWT) combined with vacuum erectile device (VED) in the treatment of DMED patients who were unresponsive to PDE5is.

METHODS

One hundred and five eligible patients were randomly divided into three groups: group A (VED), group B (Li-ESWT) and group C (VED plus Li-ESWT). Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the end of treatment. The erectile function was estimated by the international index of erectile function-erectile function domain (IIEF-EF), erection hardness score (EHS), sexual encounter profile questions 2 and 3 (SEP2 and SEP3) and global assessment question 1 and 2 (GAQ1 and GAQ2) before and after treatment. The changes of five points in IIEF-EF were calculated as the minimal clinical important difference (MCID), which was considered as the main index of efficacy.

RESULTS

The MCID was achieved in 14.7%, 14.7% and 17.6% patients in group A at the follow up on 4 weeks, 8 weeks and 12 weeks, respectively (36.4%, 39.4% and 36.4% in group B; 36.4%, 51.5%, and 66.7% in group C). There were significant differences in the percentage of MCID cases between group A and group C at the follow up on 12 weeks (<0.001), as well as that between group B and group C (=0.014). Additionally, comparison in MCID within group C showed that there were significant differences between 4 weeks and 12 weeks follow-up (=0.014).

CONCLUSION

Our findings indicated the combined therapy Li-ESWT and VED was more beneficial to shift turn PDE5is non-responders to responders for moderate patients with DMED than VED or Li-ESWT monotherapy. Moreover, this study provided evidence that patients with DMED who failed after taking oral PDE5is could attempt to opt for an alternative physicotherapy (Li-ESWT or VED) prior to more invasive alternatives.

摘要

简介

磷酸二酯酶 5 型抑制剂(PDE5i)是治疗糖尿病性勃起功能障碍(DMED)患者的一线药物,但部分患者对此类药物无反应。我们进行了一项前瞻性、随机、对照研究,以探讨低强度体外冲击波治疗(Li-ESWT)联合真空勃起装置(VED)治疗对 PDE5i 无反应的 DMED 患者的疗效。

方法

105 例符合条件的患者被随机分为三组:A 组(VED)、B 组(Li-ESWT)和 C 组(VED 加 Li-ESWT)。治疗结束后 4 周、8 周和 12 周进行随访。治疗前后采用国际勃起功能指数-勃起功能域(IIEF-EF)、勃起硬度评分(EHS)、性经历问卷 2 和 3(SEP2 和 SEP3)和全球评估问卷 1 和 2(GAQ1 和 GAQ2)评估勃起功能。计算 IIEF-EF 中 5 分的变化作为最小临床重要差异(MCID),将其作为疗效的主要指标。

结果

A 组患者在治疗后 4 周、8 周和 12 周时,MCID 的达到率分别为 14.7%、14.7%和 17.6%(B 组分别为 36.4%、39.4%和 36.4%;C 组分别为 36.4%、51.5%和 66.7%)。在治疗后 12 周时,A 组和 C 组的 MCID 病例百分比差异有统计学意义(<0.001),B 组和 C 组差异有统计学意义(=0.014)。此外,C 组内 MCID 的比较显示,4 周和 12 周随访时差异有统计学意义(=0.014)。

结论

我们的研究结果表明,与 VED 或 Li-ESWT 单独治疗相比,Li-ESWT 联合 VED 治疗对中重度 DMED 患者中 PDE5i 无反应者更有益,可以将其转为 PDE5i 反应者。此外,本研究为服用口服 PDE5i 后失败的 DMED 患者提供了证据,他们可以在选择更具侵入性的替代方案之前,尝试选择替代的物理治疗(Li-ESWT 或 VED)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/551d/9259797/5bca5be2ee49/fendo-13-937958-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验